Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04130802 · ClinicalTrials.gov registry record · Phase 2
OCS-01 in Treating Inflammation and Pain in Post-cataract Patients
A Phase 2 study, sponsored by Oculis.
- Completed
- Registry status
- Phase 2
- Development phase
- 153
- Enrollment target
NCT04130802 is a Phase 2 study that has completed, run by Oculis. The registered enrollment target is 153 participants.
The verdict
NCT04130802, a Phase 2 study, has completed, sponsored by Oculis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 153 participants
- Enrollment target
Study Summary
The DX-216 trial is a randomized, double-masked, placebo (vehicle)-controlled study evaluating the efficacy and safety of two doses of OCS-01 compared to vehicle in the treatment of inflammation and pain following cataract surgery. The primary objective is to evaluate the efficacy and safety of OCS-01 compared to placebo and the secondary objective is to evaluate the optimal dosing frequency (once a day \[QD\] or twice a day \[BID\]).
Interventions
- DRUG Placebo
- DRUG OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2019-09-27 |
| Est. Completion | 2020-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04130802
The ClinicalTrials.gov registry entry for NCT04130802 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oculis, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04130802 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04130802 about?
NCT04130802 is a clinical study titled "OCS-01 in Treating Inflammation and Pain in Post-cataract Patients". The DX-216 trial is a randomized, double-masked, placebo (vehicle)-controlled study evaluating the efficacy and safety of two doses of OCS-01 compared to vehicle in the treatment of inflammation and pain following cataract surgery. The primary objective is to evaluate the efficacy and safety of OCS-...
What is the current status of trial NCT04130802?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 153 participants. The study started on 2019-09-27. Estimated completion is 2020-01-31.
What interventions are being tested in trial NCT04130802?
The interventions under investigation include: Placebo (DRUG), OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL (DRUG).
Who is sponsoring clinical trial NCT04130802?
This trial is sponsored by Oculis, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.